Fidarestat

Fidarestat (CAS No.: 136087-85-9) is an aldose reductase inhibitor, mainly used to study the treatment of metabolic diseases such as diabetic neuropathy. Its mechanism of action involves inhibiting aldose reductase (AKR1B1), thereby reducing sorbitol accumulation and decreasing hyperglycemia-induced oxidative stress and inflammatory responses. In vitro studies show that Fidarestat can effectively inhibit aldose reductase activity at concentrations ranging from nanomolar to micromolar levels. In cell models, Fidarestat enhances the expression of antioxidant proteins by activating the Nrf2 signaling pathway, alleviating high glucose-induced oxidative stress and inflammatory responses. In animal models, Fidarestat has been used to evaluate its preventive and therapeutic effects on diabetic complications; the doses or concentrations used in experiments typically depend on the experimental design and research objectives.